Potential considerations include: Theoretical concern about promoting angiogenesis in existing tumors (not demonstrated but mechanistically plausible) Possible interactions with dopaminergic medications Limited human safety data due to absence of completed clinical trials GHK-Cu Side Effects# GHK-Cu has an established safety profile, particularly for topical use: Topical formulations are generally well-tolerated with low irritation potential Allergic reactions are rare but possible, particularly in individuals with copper sensitivity Injection site reactions (redness, swelling) can occur with subcutaneous administration No significant systemic side effects reported at standard research doses The extensive commercial use of GHK-Cu in cosmetic products provides a broader real-world safety dataset compared to BPC-157
Without enough of it, a person may feel tired, weak, and just not all there mentally
AOD 9604 is not an FDA-approved weight loss drug
However, individual responses vary considerably, and the degree of appetite suppression can differ from person to person and may fluctuate throughout treatment
Because NNMT activity intersects methyl donor utilization and nicotinamide handling, experimental inhibition can be used to probe pathway level relationships among methyl economy balance, NAD+ salvage flux, and downstream metabolic signaling in a range of preclinical systems
